Arrowhead Pharmaceuticals Stock (NASDAQ:ARWR)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$18.60

52W Range

$17.05 - $39.83

50D Avg

$20.00

200D Avg

$24.78

Market Cap

$2.33B

Avg Vol (3M)

$1.06M

Beta

0.93

Div Yield

-

ARWR Company Profile


Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

525

IPO Date

Dec 16, 1993

Website

ARWR Performance


ARWR Financial Summary


Sep 23Sep 22Sep 21
Revenue$240.74M$243.23M$138.29M
Operating Income$-205.00M$-178.51M$-149.04M
Net Income$-205.28M$-176.49M$-140.85M
EBITDA$-188.16M$-178.51M$-140.77M
Basic EPS$-1.92$-1.67$-1.36
Diluted EPS$-1.92$-1.67$-1.36

Fiscal year ends in Sep 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Aug 08, 24 | 9:08 PM
Q2 24May 09, 24 | 12:00 AM
Q1 24Feb 06, 24 | 9:28 PM

Peer Comparison


TickerCompany
IONSIonis Pharmaceuticals, Inc.
INCYIncyte Corporation
APLSApellis Pharmaceuticals, Inc.
BPMCBlueprint Medicines Corporation
DAWNDay One Biopharmaceuticals, Inc.
BMRNBioMarin Pharmaceutical Inc.
CTMXCytomX Therapeutics, Inc.
PRQRProQR Therapeutics N.V.
TERNTerns Pharmaceuticals, Inc.
ANNXAnnexon, Inc.
ASMBAssembly Biosciences, Inc.
WVEWave Life Sciences Ltd.
NLTXNeurogene Inc.
KRTXKaruna Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals, Inc.